Editor’s note

The industry will always find ways to slip through legal loopholes. Will regulators catch up in 2020?

Wide price deviation between countries offering cheaper medications indicates the complexity of drug pricing strategies across…

With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…

While regulators and pharma companies try to understand if it is the product or the process that is at fault in the ranitidine…

Multiple warning letters call for renewed rigour to fix recurring lapses and instil a stronger quality compliance system

New and existing pharma facilities will have to meet higher benchmarks to ensure that they do not pollute the environment…

Pharma companies should not be the ones held responsible for the high prices of medicines

The CBI has reportedly found cases with the same modus operandi: failing batches and then approving them for a price

The second patent cliff is around the corner, as patents for branded molecules with cumulative global sales of over $ 251 billion…

The RCEP negotiation is one of the BJP-led NDA-2 government’s first challenges as it links directly to the stated goal to make…